1 Day 1D

5 Days 5D

1 Month 1M

6 Months 6M


1 Year 1Y

5 Years 5Y

About Nevro Corp

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in =65% of patients across six peer-reviewed clinical studies. The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro's proprietary HF10® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.
D.Keith Grossman

1800 Bridge Pkwy
Redwood City, California 94065-1164
Phone: 16502510005


Nevro''s Return On Capital Employed Overview
Aug 11, 2022 14:03pm

According to data from Benzinga Pro, during Q2, Nevro ''s (NYSE: NVRO ) reported sales totaled $104.21 million. Despite a 27.2% increase in earnings, the company posted a loss of $24.99 million. Nevro collected $87.84 million in revenue during Q1, but reported earnings showed a $34.33 million loss. What Is Return On Capital Employed? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth … Full story available on Benzinga.com

Nevro Corp. (NVRO) CEO Keith Grossman on Q2 2022 Results - Earnings Call Transcript
Aug 07, 2022 03:27am

Nevro Corp. (NYSE:NYSE:NVRO) Q2 2022 Earnings Conference Call August 3, 2022 4:30 PM ET Company Participants Julie Dewey - Corporate Communications & IR Officer Keith Grossman -…

Source:Seeking Alpha
Nevro Corp. 2022 Q2 - Results - Earnings Call Presentation (NYSE:NVRO)
Aug 07, 2022 00:29am

The following slide deck was published by Nevro Corp.

Source:Seeking Alpha
Nevro Corp PT Lowered to $75 at JMP Securities
Aug 05, 2022 07:34am


Nevro Corp PT Lowered to $86 at Wells Fargo
Aug 04, 2022 10:36am


Recap: Nevro Q2 Earnings
Aug 03, 2022 20:57pm

Nevro (NYSE: NVRO ) reported its Q2 earnings results on Wednesday, August 3, 2022 at 04:05 PM. Here''s what investors need to know about the announcement. Earnings Nevro beat estimated earnings by 13.41%, reporting an EPS of $-0.71 versus an … Full story available on Benzinga.com

Nevro Q2 results mixed, co cuts FY 2022 revenue guidance, sees wider FY adj. EBITDA loss
Aug 03, 2022 20:30pm

Nevro press release (NVRO): Q2 GAAP EPS of -$0.71 beats by $0.09.Revenue of $104.21M (+1.8% Y/Y) misses by $0.26M.Sees FY 2022 revenue of $400 million to $410…

Source:Seeking Alpha
Nevro Reports Second Quarter 2022 Financial Results, Provides Third Quarter 2022 Guidance and Updates Full-Year 2022 Guidance
Aug 03, 2022 20:05pm

REDWOOD CITY, Calif., Aug. 3, 2022 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for the second quarter ended June 30, 2022, provided guidance for the third quarter of…

Source:PR Newswire Media
Nevro Q2 2022 Earnings Preview (NYSE:NVRO)
Aug 02, 2022 21:35pm

Nevro (NVRO) is scheduled to announce Q2 earnings results on Wednesday, August 3rd, after market close.The consensus EPS Estimate is -$0.79 and the consensus Revenue Estimate is…

Source:Seeking Alpha
Boston Scientific to pay Nevro $85M to settle rest of patent litigation
Aug 01, 2022 00:00am

Nevro (NYSE:NVRO) and Boston Scientific (NYSE:BSX) announced today that they reached a settlement over intellectual property litigations. The settlement gives Boston Scientific the freedom to operate using the features and capabilities embodied in its current line of products for frequencies below 1,500 Hz, with Nevro given the freedom to operate using the features and capabilities […]

Fresh Data-Based Insight On Nevro Corp. (NVRO)
Jul 23, 2022 11:00am

Nevro Corp. (NYSE:NVRO) concluded the trading at $44.17 on Friday, July 22 with a rise of 1.05% from its closing price on previous day. Taking a look at stock we notice that its last check on previous day was $43.71 and 5Y monthly beta was reading 1.03 with its price kept floating in the range … Fresh Data-Based Insight On Nevro Corp. (NVRO) Read More »

Source:Stocks Register
Nevro Corp. (NYSE: NVRO) Is An Exciting Stock To Watch.
Jul 16, 2022 13:30pm

Nevro Corp. (NYSE:NVRO) shares, rose in value on Friday, 07/15/22, with the stock price up by 0.09% to the previous day’s close as strong demand from buyers drove the stock to $42.71. Actively observing the price movement in the last trading, the stock closed the session at $42.67, falling within a range of $42.13 and … Nevro Corp. (NYSE: NVRO) Is An Exciting Stock To Watch. Read More »

Source:Stocks Register
Nevro to Report Second Quarter 2022 Financial Results
Jul 06, 2022 11:00am

Source:Kwhen Finance
Nevro Corp. (NYSE: NVRO): A Sinfully Good Stock To Watch
Jun 18, 2022 11:00am

Nevro Corp. (NYSE:NVRO) price on Friday, June 17, rose 3.23% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $42.17. A look at the stock’s price movement, the close in the last trading session was $40.85, moving within a range at $41.41 and $43.75. The beta value (5-Year … Nevro Corp. (NYSE: NVRO): A Sinfully Good Stock To Watch Read More »

Source:Stocks Register